Abstract No. 
2020 San Antonio Breast Cancer Symposium
Dec 8-11

Evaluation of SGN-LIV1a followed by AC in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL

Beckwith H, Schwab R, Yau C, Stringer-Reasor E, Wei S, Chien AJ, Albain KS, Kalinsky K, Wallace A, Elias A, Yee D, Clark AS, Boughey JC, Han H, Nanda R, Isaacs C, Mitri Z, Lang JE, Thomas A, Sanft T, DeMichele A, Perlmutter J, Rugo HS, Hylton NM, Symmans WF, Melisko ME, van't Veer LJ, I-SPY 2 Consortium, Wilson A, Asare SM, Sanil A, Berry DA, Esserman LJ

coming soon

View original